Related Experiment Video
Updated: Jan 23, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
ZBTB46, SPDEF, and ETV6: Novel Potential Biomarkers and Therapeutic Targets in Castration-Resistant Prostate Cancer
AbdulFattah Salah Fararjeh1, Yen-Nien Liu2,3,4
1PhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan. d621104004@tmu.edu.tw.
Abstract:
Prostate cancer (PCa) is the second most common killer among men in Western countries. Targeting androgen receptor (AR) signaling by androgen deprivation therapy (ADT) is the current therapeutic regime for patients newly diagnosed with metastatic PCa. However, most patients relapse and become resistant to ADT, leading to metastatic castration-resistant PCa (CRPC) and eventually death. Several proposed mechanisms have been proposed for CRPC; however, the exact mechanism through which CRPC develops is still unclear. One possible pathway is that the AR remains active in CRPC cases. Therefore, understanding AR signaling networks as primary PCa changes into metastatic CRPC is key to developing future biomarkers and therapeutic strategies for PCa and CRPC. In the current review, we focused on three novel biomarkers (ZBTB46, SPDEF, and ETV6) that were demonstrated to play critical roles in CRPC progression, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) drug resistance, and the epithelial-to-mesenchymal transition (EMT) for patients treated with ADT or AR inhibition. In addition, we summarize how these potential biomarkers can be used in the clinic for diagnosis and as therapeutic targets of PCa.
Insights
Prostate cancer (PCa) progression to castration-resistant PCa (CRPC) involves unclear mechanisms. This review highlights three biomarkers (ZBTB46, SPDEF, ETV6) crucial for understanding CRPC development and resistance to therapy.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Prostate cancer (PCa) is a leading cause of cancer death in men.
- Androgen deprivation therapy (ADT) is standard for metastatic PCa but often leads to castration-resistant PCa (CRPC).
- The precise mechanisms driving CRPC development remain incompletely understood, though AR signaling persistence is implicated.
Purpose of the Study:
- To review novel biomarkers involved in CRPC progression.
- To explore the roles of ZBTB46, SPDEF, and ETV6 in CRPC.
- To discuss the clinical utility of these biomarkers for diagnosis and therapy.
Main Methods:
- Literature review focusing on recent studies of CRPC mechanisms.
- Analysis of the roles of ZBTB46, SPDEF, and ETV6 in AR signaling and treatment resistance.
- Synthesis of information on biomarker potential in clinical settings.
Main Results:
- ZBTB46, SPDEF, and ETV6 are identified as key players in CRPC.
- These biomarkers are linked to resistance against androgen deprivation therapy (ADT) and EGFR TKI.
- They also play a role in epithelial-to-mesenchymal transition (EMT) during CRPC progression.
Conclusions:
- Understanding AR signaling in CRPC is vital for new therapeutic strategies.
- ZBTB46, SPDEF, and ETV6 show promise as diagnostic and therapeutic targets for PCa and CRPC.
- Further research into these biomarkers could improve patient outcomes.
Related Concept Videos
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Resistivity
Resistance
Therapeutic Index
Potential Energy
Chemical bonds that form attractive forces between atoms also contain potential energy, called chemical energy. When a chemical reaction...

